Loading data for TECH — first visit, this takes a few seconds.

알림

Bio-Techne Corporation (TECH)

NasdaqGS: TECH · 실시간 가격 · USD

72.22

-0.17 (-0.23%)

종가 기준: Aug 18, 2026, 3:59 PM

72.12

-0.14%

프리마켓: 4:05 AM

-0.23% (1D)

매수호가	n/a
시가총액	11.25B
매출 (ttm)	1.22B
순이익 (ttm)	181.86M
베타	1.28
EPS (ttm)	1.16
P/E (ttm)	62.26
선행 P/E	31.17
P/B (ttm)	5.42
P/S (ttm)	9.26
Earnings Date	Nov 9, 2026

매도호가	n/a
거래량	2,533,222
평균 거래량 (20일)	4,828,153
시가	72.41
전일 종가	72.39
일중 범위	72.22 - 72.52
52주 범위	43.20 - 72.62
애널리스트	n/a
목표주가	n/a
배당	$0.32 (0.44%)
배당락일	2026년 8월 24일

TECH 소개

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cel...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Feb 9, 1989

직원 수 3,000

상장 거래소 NasdaqGS

티커 TECH

웹사이트 https://www.bio-techne.com

전체 기업 정보

재무 실적

2025년 Bio-Techne의 매출은 1.22B로, 전년 1.16B 대비 5.23% 증가했습니다. 순이익은 73.4M로, -56.34% 감소했습니다.

재무제표

어닝 서프라이즈

Bio-Techne가 Aug 12, 2026에 분기 실적을 발표했습니다:

매출 $311.42M 예상치 하회 $0, 및 -1.51% 전년 대비 감소.

EPS 0.52 예상치 하회 0.00, 및 -1.89% 전년 대비 감소.

다음 실적 발표

Bio-Techne Corporation의 실적 발표 예정일은 Nov 9, 2026, 장 시작 전입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

19시간 전 · Barchart

Is Wall Street Bullish or Bearish on Bio-Techne Stock?

Bio-Techne has outperformed the broader market over the past year, but analysts are cautious about the stock’s prospects.

1일 전 · StockStory

3 High-Flying Stocks We Approach with Caution

“You get what you pay for” often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the premium, they typically experience elevated...

5일 전 · Zacks

TECH Q4 Earnings Meet Estimates, Revenues Surpass, Stock Rises

Bio-Techne's Q4 revenues beat estimates as Diagnostics and Spatial Biology deliver strong organic growth, while its Merck deal remains in focus.

6일 전 · StockStory

Bio-Techne (NASDAQ:TECH) Surprises With Q2 CY2026 Sales

Life sciences company Bio-Techne (NASDAQ:TECH) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 1.3% year on year to $321.2 million. Its non-GAAP profit of $0.52 pe...

1주 전 · Simply Wall St.

Is Bio-Techne (TECH) Above Fair Value After A 44% Return?

Bio-Techne stock has delivered a strong 44.2% return over the past year, yet both its Discounted Cash Flow (DCF) intrinsic value estimate and market multiples currently point to the shares trading at ...

2 페이지 중 1

Bio-Techne Corporation (TECH)